SYRE.NASDAQSpyre Therapeutics, INC
10-Q/A: Spyre Therapeutics Amends Quarterly Report Due to Accounting Error, Identifies Material Weakness
Sentiment:
Quarterly Report Amendment
Spyre Therapeutics has amended its quarterly report for the period ended September 30, 2024, due to a misapplication of U.S. GAAP related to the calculation of net loss per share and has identified a material weakness in internal control over financial reporting.
Capital raiseThe company has a $500 million shelf registration statement in place.The company has a sales agreement with TD Securities (USA) LLC for at-the-market offerings of up to $200 million.The company sold 426,287 shares of common stock under the ATM at a price per share of $28.15, resulting in net proceeds of $11.8 million.
Worse than expectedThe company had to restate its financial statements due to a misapplication of U.S. GAAP.A material weakness in internal control over financial reporting was identified.The company reported a significant net loss for the quarter and year-to-date.
Summary
- Spyre Therapeutics has filed an amendment to its quarterly report for the period ending September 30, 2024, due to an error in the calculation of basic and diluted net loss per share.
- The company incorrectly excluded its Series A and Series B non-voting convertible preferred stock from the net loss per share calculation.
- This error led to a restatement of the financial statements and the identification of a material weakness in internal control over financial reporting.
- The amendment includes updated financial statements, a re-evaluation of disclosure controls, and new certifications from the CEO and CFO.
- The company's cash and cash equivalents totaled $71.6 million, and marketable securities were $342.6 million as of September 30, 2024.
- The company reported a net loss of $69.0 million for the three months ended September 30, 2024, and $151.7 million for the nine months ended September 30, 2024.
- The company has sufficient resources to fund operations for at least one year from the issuance date of these financial statements.
Sentiment
Score: 4
Explanation: The document reveals significant issues including a material weakness in internal controls and a restatement of financials, which are negative signals. However, the company has a strong cash position and has taken steps to address the issues, which provides some reassurance.
Positives
- The company has a strong cash position with $71.6 million in cash and cash equivalents and $342.6 million in marketable securities.
- The company has sufficient resources to fund operations for at least one year.
- The company has access to additional capital through a $500 million shelf registration statement.
- The company has taken steps to correct the accounting error and is implementing a remediation plan to address the material weakness.
Negatives
- The company identified a material weakness in internal control over financial reporting related to the earnings per share calculation.
- The company had to restate its financial statements due to a misapplication of U.S. GAAP.
- The company reported a significant net loss of $69.0 million for the three months ended September 30, 2024, and $151.7 million for the nine months ended September 30, 2024.
Risks
- The company's ongoing losses and need for additional financing pose a risk to its future operations.
- The material weakness in internal control over financial reporting could lead to future misstatements.
- The company's reliance on external funding and the potential for delays in drug development could impact its financial stability.
- The company's success is dependent on the successful development and commercialization of its drug candidates.
Future Outlook
Based on current operating plans, the Company has sufficient resources to fund operations for at least one year from the issuance date of these financial statements with existing cash, cash equivalents, and marketable securities. Spyre will need to secure additional financing in the future to fund additional research and development, and before a commercial drug can be produced, marketed and sold.
Management Comments
- Management identified an error related to the calculation and presentation of loss per share.
- Management concluded that the company did not design and maintain effective controls related to the earnings per share calculation.
- Management believes that the actions taken will remediate the material weakness.
- Management has concluded that the consolidated financial statements present fairly, in all material respects, the financial position, results of operations and cash flows for the periods presented.
Industry Context
This announcement highlights the challenges faced by clinical-stage biotechnology companies, particularly in maintaining accurate financial reporting while rapidly evolving. The need for robust internal controls and adherence to accounting standards is crucial for investor confidence in this sector. The company's focus on inflammatory bowel disease aligns with a growing area of unmet medical need and significant market potential.
Comparison to Industry Standards
- The restatement of financial results due to an accounting error is not uncommon in the biotechnology industry, especially for companies with complex financial instruments like convertible preferred stock.
- Companies like Madrigal Pharmaceuticals and Viking Therapeutics have also experienced significant fluctuations in their stock prices due to clinical trial results and regulatory updates, highlighting the inherent volatility in the sector.
- The identification of a material weakness in internal control over financial reporting is a serious issue that requires immediate remediation, similar to what other companies like Cassava Sciences have faced.
- The company's cash runway of at least one year is comparable to other clinical-stage biotech companies, but the need for future financing is a common challenge.
- The company's focus on inflammatory bowel disease is a competitive space with companies like Takeda and AbbVie also developing treatments in this area.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Medical Officer | Sheldon Sloan, M.D., M. Bioethics | 2024-10-01 | New appointment |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Control | Identified a material weakness in internal control over financial reporting related to the earnings per share calculation. | 2024-09-30 | Requires remediation and could lead to future misstatements if not addressed. |
Related Party Transactions
- The company has significant related party transactions with Paragon Therapeutics, Inc. and Parapyre Holding LLC.
- The company is obligated to compensate Paragon for its services performed under each research program based on the actual costs incurred with mark-up costs.
- The company is obligated to issue Parapyre annual equity grants of warrants.
- The company recognized $21.2 million in related party expenses for the nine months ended September 30, 2024.
Stakeholder Impact
- Shareholders are impacted by the restatement of financial results and the identification of a material weakness.
- Employees may be impacted by the ongoing restructuring and changes in management.
- Customers and suppliers may be impacted by the company's financial stability and ability to continue operations.
- Creditors may be impacted by the company's ongoing losses and need for additional financing.
Next Steps
- The company will enhance the design of the control relevant to the calculation of net earnings (loss) per share calculations and disclosures.
- The company will continue to test the effectiveness of the remediated controls.
- The company will continue to develop its pipeline of antibody therapeutics for inflammatory bowel disease.
- The company will continue to explore strategic alternatives to maximize stockholder value.
Key Dates
| Date | Description |
|---|---|
| 2013-12-16 | Aeglea BioTherapeutics Holdings, LLC formed in Delaware. |
| 2015-03-10 | Aeglea BioTherapeutics Holdings, LLC converted to a Delaware corporation. |
| 2019-02-01 | Issuance of pre-funded warrants. |
| 2020-04-01 | Issuance of pre-funded warrants. |
| 2022-05-31 | Issuance of pre-funded warrants. |
| 2023-04-12 | Company initiated a process to explore strategic alternatives and implemented a restructuring plan. |
| 2023-06-22 | Company acquired the assets of Spyre Therapeutics, Inc. (Pre-Merger Spyre). |
| 2023-06-26 | Company completed a private placement of Series A Preferred Stock. |
| 2023-07-03 | Record date for distribution of contingent value rights (CVR). |
| 2023-07-07 | Common Stock and Series A Preferred Stock issued to Pre-Merger Spyre stockholders. |
| 2023-07-12 | Company exercised option for SPY001 research program. |
| 2023-07-27 | Company sold global rights to pegzilarginase to Immedica. |
| 2023-09-08 | Company effected a reverse stock split of its Common Stock at a ratio of 1-for-25. |
| 2023-11-21 | Stockholders approved the issuance of Common Stock upon conversion of Series A Preferred Stock. |
| 2023-11-22 | Mark McKenna granted stock options under consulting agreement. |
| 2023-11-27 | Company completed its corporate rebranding, changing the name of the Company to Spyre Therapeutics, Inc. |
| 2023-12-11 | Company completed a private placement of Common Stock and Series B Preferred Stock. |
| 2023-12-14 | Company exercised option for SPY002 research program. |
| 2023-12-31 | Company settled its 2023 obligation under the Parapyre Option Obligation. |
| 2024-01-01 | Additional shares became available for issuance under the 2016 Plan due to the Evergreen Provision. |
| 2024-02-01 | Mark McKenna appointed as a Class I director. |
| 2024-03-18 | Company filed a certificate of amendment to its Series B Certificate of Designation. |
| 2024-03-20 | Company completed a private placement of Series B Preferred Stock. |
| 2024-04-23 | Company entered into an exchange agreement with Fairmount Healthcare Fund II L.P. |
| 2024-04-25 | April 2024 Exchange closed. |
| 2024-05-14 | Stockholders approved the issuance of Common Stock upon conversion of Series B Preferred Stock; Company and Paragon entered into SPY001 and SPY002 License Agreements. |
| 2024-06-05 | Company exercised option for SPY003 research program. |
| 2024-07-01 | Aeglea Employees and Directors stock based compensation expense begins. |
| 2024-09-06 | Company filed a new shelf registration statement on Form S-3. |
| 2024-09-30 | End of the reporting period for the amended quarterly report. |
| 2024-10-01 | Sheldon Sloan, M.D., M. Bioethics, appointed as Chief Medical Officer. |
| 2024-10-11 | Company and Paragon entered into the SPY003 License Agreement. |
| 2024-11-01 | Shares of common stock outstanding as of this date. |
| 2024-11-07 | Original filing date of the Form 10-Q. |
| 2024-11-18 | Date of the amended filing of the Form 10-Q/A. |
Keywords
Spyre Therapeutics, financial restatement, material weakness, internal control, net loss per share, preferred stock, biotechnology, GAAP, financial reporting, at-the-market offering, shelf registration
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.